Increasing evidence of pathogenic role of the Mediator (MED) complex in the development of cardiovascular diseases.

Cardiovascular diseases (CVDs) are the first cause of death in the World. Mediator (MED) is an evolutionarily conserved protein complex, which mediates distinct protein-protein interactions. Pathogenic events in MED subunit have been associated with human diseases. Novel increasing evidence showed that missense mutations in MED13L gene are associated with transposition of great arteries while MED12, MED13, MED15, and MED30, have been correlated with heart development. Moreover, MED23 and MED25 have been associated with heart malformations in humans. Relevantly, MED1, MED13, MED14, MED15, MED23, MED25, and CDK8, were found modify glucose and/or lipid metabolism. Indeed, MED1, MED15, MED25, and CDK8 interact in the PPAR- and SREBP-mediated signaling pathways. MED1, MED14 and MED23 are involved in adipocyte differentiation, whereas MED23 mediates smooth muscle cell differentiation. MED12, MED19, MED23, and MED30 regulate endothelial differentiation by alternative splicing mechanism. Thus, MEDs have a central role in early pathogenic events involved in CVDs representing novel targets for clinical prevention and therapeutic approaches. • MED gene modifications induce heart malformations. • MED12, MED13, MED15, and MED30, have been correlated with heart development. • MED13L, MED23 and MED25 have been associated with heart malformations in human. • MED1, MED15, MED25, and CDK8 deregulate energy homeostasis. • MED12, MED19, MED23, and MED30 regulate endothelial differentiation by splicing. [ABSTRACT FROM AUTHOR]